You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1377 Preclinical characterization of D3L-001, a novel bispecific antibody that enhance phagocytosis and eradication of HER2 positive solid tumor via HER2 and CD47 dual blockade

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1377 Preclinical characterization of D3L-001, a novel bispecific antibody that enhance phagocytosis and eradication of HER2 positive solid tumor via HER2 and CD47 dual blockade
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address